Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Neurosurgery. 2013 Sep;73(3):401-10. doi: 10.1227/01.neu.0000431471.64289.3d.
Stereotactic radiosurgery (SRS) is an important option for patients with cavernous sinus meningiomas.
To evaluate cranial nerve outcomes in patients who underwent SRS for cavernous sinus meningiomas with or without prior microsurgery.
During a 23-year interval, 272 patients underwent Gamma Knife SRS for cavernous sinus meningiomas (70 men, 202 women; median age, 54 years). In this series, 99 patients underwent prior microsurgical resection. The median tumor volume was 7.9 cm and median marginal dose was 13 Gy. The median follow-up period was 62 months (range, 6-209 months).
The progression-free survival after SRS was 96% at 3 years, 94% at 5 years, and 86% at 10 years. After SRS, 13 of 91 patients (14%) who underwent prior microsurgery had improvement of preexisting cranial nerve symptoms or signs. In comparison, 54 of 145 patients (37%) without prior microsurgery had improvement of preexisting cranial nerve symptoms or signs. The improvement rate of cranial nerve deficits after SRS in patients without prior microsurgery was 20% at 1 year, 34% at 2 years, 36% at 3 years, and 39% at 5 years. Patients who had not undergone prior microsurgery had significantly higher improvement rates of preexisting cranial nerve symptoms and signs (P = .001). After SRS, 29 patients (11%) developed new or worsened cranial nerve function.
SRS provided long-term effective tumor control and a low risk of new cranial nerve deficits. Improvement in preexisting cranial neuropathies was detected in significantly more patients who had not undergone prior microsurgical procedures.
立体定向放射外科(SRS)是治疗海绵窦脑膜瘤患者的重要选择。
评估接受 SRS 治疗海绵窦脑膜瘤患者的颅神经结局,这些患者中有或无先前的显微手术。
在 23 年的时间间隔内,272 例患者接受伽玛刀 SRS 治疗海绵窦脑膜瘤(70 例男性,202 例女性;中位年龄 54 岁)。在本系列中,99 例患者接受了先前的显微切除术。中位肿瘤体积为 7.9cm,中位边缘剂量为 13Gy。中位随访时间为 62 个月(范围为 6-209 个月)。
SRS 后 3 年、5 年和 10 年无进展生存率分别为 96%、94%和 86%。SRS 后,在 91 例先前接受过显微手术的患者中有 13 例(14%)出现了先前存在的颅神经症状或体征的改善。相比之下,在 145 例未行先前手术的患者中有 54 例(37%)出现了先前存在的颅神经症状或体征的改善。在未行先前手术的患者中,SRS 后颅神经缺陷的改善率在 1 年时为 20%,在 2 年时为 34%,在 3 年时为 36%,在 5 年时为 39%。未行先前手术的患者颅神经症状和体征的改善率显著更高(P=0.001)。SRS 后,29 例(11%)患者出现新发或加重的颅神经功能障碍。
SRS 提供了长期有效的肿瘤控制和新发颅神经损伤的低风险。在未行先前显微手术的患者中,更多的患者检测到先前存在的颅神经疾病得到改善。